RSS

Janssen

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

Marketing authorisation for Darzalex (daratumumab), from the Janssen Pharmaceutical Companies of Johnson & Johnson, to be used as a frontline treatment for newly diagnosed patients with multiple myeloma has been granted by the European Commission. Read more

News

The Janssen Pharmaceutical Companies of Johnson & Johnson has reported the positive topline results from the ATLAS Phase III study investigating a novel, long acting injectable two-drug regimen for the treatment of HIV-1. Read more

News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended broadening the existing marketing authorisation for Janssen’s Darzalex (daratumumab) as a frontline treatment. Read more

News

Following a planned review, the Data Monitoring Committee (DMC) has recommended termination of the Phase Ib/II study of daratumumab in combination with atezolizumab versus atezolizumab monotherapy in patients with previously treated NSCLC Read more

News

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir/rilpivirine) — a two-drug regimen, once-daily, single pill for the treatment of HIV-1. Read more

News

The Janssen Pharmaceutical Companies of Johnson & Johnson, have announced the positive results from two Phase III clinical studies of esketamine nasal spray for the treatment of patients with treatment-resistant depression. Read more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

The National Institute for Health and Care Excellence (NICE) has issued its final appraisal determination (FAD) to Janssen recommending Tremfya (guselkumab) for treatment of adults with moderate to severe plaque psoriasis. Read more

News

Janssen has announced that its treatment for moderate-to-severe plaque psoriasis is now available in the UK for adult patients who are candidates for systemic therapy. Read more

News

Janssen has announced that the European Commission (EC) has approved its darunavir-based single-tablet regimen (STR), Symtuza▼, for the treatment of HIV-1 in adults and adolescents in Europe. Read more

News

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the marketing authorisation in the EU for Janssen-Cilag International’s guselkumab — a treatment for moderate to severe plaque psoriasis. Read more

News